Ipca Labs

In Q3, Ipca's operating profit margin was lowest since FY19, impacted by lower gross margins, and continued higher overheads.

The recent price hike, analysts said, brings some respite for the industry facing multiple headwinds such as steep raw inflation, price erosion in the US market and higher freight costs.

The world's race for a coronavirus drug hinges on Indian companies working with their global peers. Business Standard tracks six companies to feel the pulse of Indian pharma

In the broader markets, the BSE MidCap index added 0.7 per cent while the BSE SmallCap index gained 1.2 per cent.

The pharmaceutical company has fixed Tuesday, January 11, 2022, as the 'record date' for the members entitlement of sub-divided shares.

Ipca Labs has tripled in the last one year from the lows of Rs 817 and continues to hold the same strength and momentum. Charts indicate more headroom from the current levels

In Q2FY21, the company's Ebitda margins are likely to improve 740 basis points YoY to 28 per cent

With markets recovering, midcaps have also rebounded and in fact, have outperformed benchmark indices by a good margin in the last two months

There is a lot of uncertainty and clear trend is not visible on the charts

The SGX Nifty is up around 170 points from yesterday's close and is indicating an open at around 9,980 levels for the Nifty today

SGX Nifty, which is up 130 points, is indicating a stronger opening for the Indian indices today

Ipca's Zerodol brand and its multiple variants used in treating pain and inflammation are an example of how this trend is playing out

Technical Calls by Gaurav Garg, Head of Research at CapitalVia Global Research Limited- Investment Advisor

Bharti Airtel's move remained resilient during the downtrend which the market witnessed in the current calendar year

The primary trend of Ipca Lab's stock has been bullish with higher tops and higher bottoms on the weekly and monthly charts

The medicine is considered one of the possible treatments for the Covid-19

Ipca's first half performance holds testimony to its robust growth with India business growing in mid-teens

The United States Food and Drug Administration (USFDA) inspection of its Piparia (Silvassa) formulations manufacturing unit in August resulted in three observations, it added.

Resolution of FDA issues a key positive for the stock and should be sorted in FY16, so investors should be patient

The acquisition of a majority stake in Bayshore will allow Ipca to commercialise its registered generic drug products in the US market